Spring Bio Solution launches intelligence platform to streamline generic drug development
Spring Bio Solution has unveiled NCE Grid, described as the world’s first free NCE-1 intelligence platform designed to decode and centralise Paragraph IV filing opportunities for generic pharmaceutical companies. The Somerset, New Jersey-based company launched the platform to address what it identifies as significant inefficiencies in current drug development intelligence gathering.
Addressing fragmented pharmaceutical intelligence
The pharmaceutical industry has long struggled with tracking New Chemical Entity (NCE) exclusivity expirations and Paragraph IV filings through fragmented, manual processes. According to Spring Bio Solution, regulatory updates remain scattered across various portals, with intelligence buried in siloed databases and timelines tracked using basic spreadsheets. “We created NCE Grid because we saw too many companies struggle with fragmented insights and missed opportunities,” said Salim Shaikh, founder and CEO of Spring Bio Solution. “In a race where timing is everything, our platform brings clarity, speed, and a competitive edge to decision-makers.”
Technical capabilities and strategic applications
NCE Grid integrates critical data points including molecule information, innovator names, NCE-1 dates, revenue projections, therapeutic usage patterns, expected sales growth, and compound annual growth rate percentages into a single platform. The system provides real-time visualisations and actionable insights designed to support strategy, regulatory, and portfolio teams in identifying first-to-file opportunities.
For generic pharmaceutical companies competing for “first to file” status, intelligence gaps and missed timelines can result in lost exclusivity periods worth millions in potential revenue. The platform addresses these challenges by centralising previously disparate data sources into an intuitive interface.
Spring Bio Solution operates as a global comparator sourcing and clinical trial supplies provider, maintaining offices and wholesale drug distribution licence facilities across the United States, European Union, Singapore, and India. The company reports a network of over 400 distribution partners and relationships with 30+ innovators, supporting more than 600 clients with a 99.9% success rate for sourcing comparator drugs and reference listed drugs.
The company’s operational experience encompasses support for over 1,000 clinical trials and more than 12,000 bioequivalence studies, with cold chain capabilities ranging from minus 60°C to ambient temperatures.”
For more information, visit: https://shorturl.at/NEOq0
Digital issue: Please click here for more information
